{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:21:38Z","timestamp":1790112098619,"version":"4.0.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.maturitas.2023.04.271","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T17:24:52Z","timestamp":1683825892000},"page":"8-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Reappraising 21\u00a0years of the WHI study: Putting the findings in context for clinical practice"],"prefix":"10.1016","volume":"174","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-1552","authenticated-orcid":false,"given":"Petra","family":"Stute","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8452-1548","authenticated-orcid":false,"given":"Jo","family":"Marsden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2714-623X","authenticated-orcid":false,"given":"Angelo","family":"Cagnacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2023.04.271_bb0005","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1017\/S1092852900023166","article-title":"Perimenopausal mental disorders: epidemiology and phenomenology","volume":"10","author":"Rasgon","year":"2005","journal-title":"CNS Spectr."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0010","doi-asserted-by":"crossref","first-page":"15004","DOI":"10.1038\/nrdp.2015.4","article-title":"Menopause","volume":"1","author":"Davis","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0015","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s12905-021-01478-z","article-title":"Long term impact of the WHI studies on information-seeking and decision-making in menopause symptoms management: a longitudinal analysis of questions to a medicines call centre","volume":"21","author":"Natari","year":"2021","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e402","article-title":"Health symptoms during midlife in relation to menopausal transition: British prospective cohort study","volume":"344","author":"Mishra","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0025","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of The North American Menopause Society","volume":"29","year":"2022","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0030","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3109\/13697137.2011.570590","article-title":"Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health","volume":"14","author":"Sturdee","year":"2011","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0040","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/2053369120957514","article-title":"The British Menopause Society & Women\u2019s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women","volume":"26","author":"Hamoda","year":"2020","journal-title":"Post. Reprod. Health"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0045","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s health initiative randomized controlled trial","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0050","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1210\/jc.2012-4070","article-title":"Where are we 10 years after the women's health initiative?","volume":"98","author":"Lobo","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0055","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/13697137.2017.1291607","article-title":"Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol \u00b1 progesterone) are optimal","volume":"20","author":"L\u2019Hermite","year":"2017","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0060","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/13697137.2017.1280251","article-title":"The evidence base for HRT: what can we believe?","volume":"20","author":"Langer","year":"2017","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0065","article-title":"A critique of Women\u2019s health initiative studies (2002\u20132006)","volume":"4","author":"Clark","year":"2006","journal-title":"Nucl. Recept. Signal."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0070","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","article-title":"Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause","volume":"297","author":"Rossouw","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0075","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1056\/NEJMoa071513","article-title":"WHI and WHI-CACS investigators, estrogen therapy and coronary-artery calcification","volume":"356","author":"Manson","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0080","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/GME.0000000000001326","article-title":"The kronos early estrogen prevention study (KEEPS): what have we learned?","volume":"26","author":"Miller","year":"2019","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0085","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/01.gme.0000243569.70946.9d","article-title":"Decline in use of hormone therapy among postmenopausal women in the United Kingdom","volume":"14","author":"Menon","year":"2007","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0090","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3390\/medicina55090602","article-title":"The controversial history of hormone replacement therapy","volume":"55","author":"Cagnacci","year":"2019","journal-title":"Medicina (B Aires)."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0095","doi-asserted-by":"crossref","first-page":"10801","DOI":"10.1038\/s41598-021-90357-6","article-title":"Conjugated equine estrogen used in postmenopausal women associated with a higher risk of stroke than estradiol","volume":"11","author":"Chang","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0100","first-page":"85","article-title":"Clinical opinion: the biologic and pharmacologic principles of estrogen therapy for symptomatic menopause","volume":"8","author":"Notelovitz","year":"2006","journal-title":"MedGenMed."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bpobgyn.2020.06.002","article-title":"The pharmacodynamics and safety of progesterone","volume":"69","author":"Piette","year":"2020","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0110","first-page":"121","article-title":"Progesterone vs. Synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis, sys","volume":"5","author":"Asi","year":"2016","journal-title":"Rev."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0115","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3399\/bjgp19X706169","article-title":"The dangers of compounded bioidentical hormone replacement therapy","volume":"69","author":"Newson","year":"2019","journal-title":"Br. J. Gen. Pract."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0120","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jsbmb.2013.11.011","article-title":"Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: is it safe?","volume":"142","author":"Stanczyk","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0125","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jsbmb.2013.10.011","article-title":"Pharmacology of conjugated equine estrogens: efficacy, safety and mechanism of action","volume":"142","author":"Bhavnani","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0130","first-page":"1","article-title":"Menopausal hormone therapy in questions and answers - a manual for physicians of various specialties","volume":"18","author":"Paszkowski","year":"2019","journal-title":"Prz. Menopauzalny."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0135","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0002-9378(82)90218-6","article-title":"Comparison of pharmacodynamic properties of various estrogen formulations","volume":"144","author":"Mashchak","year":"1982","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0140","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1210\/er.2012-1008","article-title":"Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects","volume":"34","author":"Stanczyk","year":"2013","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0145","first-page":"388","article-title":"Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite\/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate","volume":"82","author":"Imthurn","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0150","first-page":"1","article-title":"Review of menopausal hormone therapy with estradiol and progesterone versus other estrogens and progestins","author":"Graham","year":"2022","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0155","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14596-5","article-title":"Million women study collaborators, breast cancer and hormone-replacement therapy in the million women study","volume":"362","author":"Beral","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0160","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/AOG.0000000000004723","article-title":"Menopausal hormone therapy formulation and breast cancer risk","volume":"139","author":"Abenhaim","year":"2022","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0165","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003731","article-title":"Menopausal hormone therapy and women\u2019s health: an umbrella review","volume":"18","author":"Zhang","year":"2021","journal-title":"PLoS Med."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0175","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/cen.14469","article-title":"Impact of menopausal hormone therapy on colorectal cancer risk - a systematic review","volume":"95","author":"Nakhostin","year":"2021","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0180","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/GME.0000000000001480","article-title":"Endometrial safety and bleeding profile of a 17\u03b2-estradiol\/progesterone oral softgel capsule (TX-001HR)","volume":"27","author":"Mirkin","year":"2020","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0185","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1080\/13697137.2016.1187123","article-title":"The impact of micronized progesterone on the endometrium: a systematic review","volume":"19","author":"Stute","year":"2016","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0190","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.3390\/cancers12082195","article-title":"Menopausal hormone therapy and risk of endometrial cancer: a systematic review","volume":"12","author":"Tempfer","year":"2020","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0195","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/aje\/kwq300","article-title":"Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European prospective investigation into cancer and nutrition","volume":"172","author":"Allen","year":"2010","journal-title":"Am.J. Epidemiol."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0200","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women's health initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0205","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1525-1497.2006.00389.x","article-title":"Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis","volume":"21","author":"Salpeter","year":"2006","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0210","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/13697137.2021.2022644","article-title":"The impact of micronized progesterone on cardiovascular events - a systematic review","volume":"25","author":"Kaemmle","year":"2022","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0215","first-page":"745","article-title":"Modification of blood pressure in postmenopausal women: role of hormone replacement therapy","volume":"6","author":"Cannoletta","year":"2014","journal-title":"Int. J. Women's Health"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0220","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0149-2918(00)88267-3","article-title":"Oral micronized progesterone","volume":"21","author":"de Ligni\u00e8res","year":"1999","journal-title":"Clin. Ther."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0225","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1080\/13697137.2019.1640197","article-title":"Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms","volume":"22","author":"Lobo","year":"2019","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0230","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/GME.0000000000001659","article-title":"Effects of combined 17\u03b2-estradiol and progesterone on weight and blood pressure in postmenopausal women of the REPLENISH trial","volume":"28","author":"Black","year":"2020","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0235","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40885-021-00175-1","article-title":"Effects of menopausal hormone therapy on ambulatory blood pressure and arterial stiffness in postmenopausal korean women with grade 1 hypertension: a randomized, placebo-controlled trial","volume":"27","author":"Yoon","year":"2021","journal-title":"Clin Hypertens."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0240","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00125-004-1448-x","article-title":"Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women\u2019s Health Initiative Hormone Trial","volume":"47","author":"Margolis","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0245","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1210\/clinem\/dgab042","article-title":"Menopausal hormone therapy and cardiovascular disease: the role of formulation, dose, and route of delivery","volume":"106","author":"Shufelt","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0260","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1476-511X-11-133","article-title":"Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial","volume":"11","author":"Casanova","year":"2012","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0265","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1210\/jcem-73-2-373","article-title":"Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women","volume":"73","author":"Moorjani","year":"1991","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0270","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/j.1538-7836.2012.04919.x","article-title":"Million women study collaborators, venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study","volume":"10","author":"Sweetland","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0275","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/CIRCULATIONAHA.106.642280","article-title":"Estrogen and thromboembolism risk (ESTHER) study group, hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study","volume":"115","author":"Canonico","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0280","series-title":"Poster 11299 ISGE Congress, Florence","article-title":"Venous thromboembolism risk in menopausal women treated with oral estradiol\/micronised progesterone versus conjugated estrogens\/medroxyprogesterone: a claims data analysis in the United States","author":"Panay","year":"2022"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0285","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00125-004-1448-x","article-title":"Women\u2019s health initiative investigators, effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women\u2019s health initiative hormone trial","volume":"47","author":"Margolis","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0290","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0295","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.287.20.2668","article-title":"Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women","volume":"287","author":"Lindsay","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0300","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1210\/er.2001-5002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women","volume":"23","author":"Wells","year":"2002","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0305","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1200\/JCO.2012.42.7732","article-title":"Estrogen plus progestin and colorectal cancer incidence and mortality","volume":"30","author":"Simon","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2023.04.271_bb0310","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ijc.26026","article-title":"The effect of estrogen vs. Combined estrogen-progestogen therapy on the risk of colorectal cancer","volume":"130","author":"Lin","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0315","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017639","article-title":"Menopausal hormone therapy and colorectal cancer: a linkage between nationwide registries in Norway","volume":"7","author":"Botteri","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0320","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/ijc.25504","article-title":"Menopausal hormone therapy and risk of colorectal cancer in the European prospective investigation into cancer and nutrition","volume":"128","author":"Tsilidis","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.maturitas.2023.04.271_bb0325","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/aje\/kwu146","article-title":"Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992\u20132008","volume":"180","author":"Fournier","year":"2014","journal-title":"Am. J. Epidemiol."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512223003584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512223003584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:21:44Z","timestamp":1759915304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512223003584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":62,"alternative-id":["S0378512223003584"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2023.04.271","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reappraising 21\u00a0years of the WHI study: Putting the findings in context for clinical practice","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2023.04.271","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}